Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008-2015)
| dc.rights.license | open | en_US |
| dc.contributor.author | SABATE, M. | |
| dc.contributor.author | VIDAL, X. | |
| dc.contributor.author | BALLARIN, E. | |
| dc.contributor.author | ROTTENKOLBER, M. | |
| dc.contributor.author | SCHMIEDL, S. | |
| dc.contributor.author | GRAVE, B. | |
| dc.contributor.author | HUERTA, C. | |
| dc.contributor.author | MARTIN-MERINO, E. | |
| dc.contributor.author | MONTERO, D. | |
| dc.contributor.author | LEON-MUNOZ, L. M. | |
| dc.contributor.author | GASSE, C. | |
| dc.contributor.author | MOORE, Nicholas | |
| dc.contributor.author | DROZ, C. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | LASSALLE, Regis | |
| dc.contributor.author | AAKJAER, M. | |
| dc.contributor.author | ANDERSEN, M. | |
| dc.contributor.author | DE BRUIN, M. L. | |
| dc.contributor.author | SOUVEREIN, P. | |
| dc.contributor.author | KLUNGEL, O. H. | |
| dc.contributor.author | GARDARSDOTTIR, H. | |
| dc.contributor.author | IBANEZ, L. | |
| dc.date.accessioned | 2022-01-17T10:09:20Z | |
| dc.date.available | 2022-01-17T10:09:20Z | |
| dc.date.issued | 2021-11-03 | |
| dc.identifier.issn | 1663-9812 (Print) 1663-9812 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/124403 | |
| dc.description.abstractEn | Aims: To describe and compare the adherence to different direct oral anticoagulants (DOACs) in eight European databases representing six countries. Methods: Longitudinal drug utilization study of new users (≥18 years) of DOACs (dabigatran, rivaroxaban, apixaban) with a diagnosis of non-valvular atrial fibrillation (2008-2015). Adherence was examined by estimating persistence, switching, and discontinuation rates at 12 months. Primary non-adherence was estimated in BIFAP and SIDIAP databases. Results: The highest persistence rate was seen for apixaban in the CPRD database (81%) and the lowest for dabigatran in the Mondriaan database (22%). The switching rate for all DOACs ranged from 2.4 to 13.1% (Mondriaan and EGB databases, respectively). Dabigatran had the highest switching rate from 5.0 to 20.0% (Mondriaan and EGB databases, respectively). The discontinuation rate for all DOACs ranged from 16.0 to 63.9% (CPRD and Bavarian CD databases, respectively). Dabigatran had the highest rate of discontinuers, except in the Bavarian CD and AOK NORDWEST databases, ranging from 23.2 to 64.6% (CPRD and Mondriaan databases, respectively). Combined primary non-adherence for examined DOACs was 11.1% in BIFAP and 14.0% in SIDIAP. There were differences in population coverage and in the type of drug data source among the databases. Conclusion: Despite the differences in the characteristics of the databases and in demographic and baseline characteristics of the included population that could explain some of the observed discrepancies, we can observe a similar pattern throughout the databases. Apixaban was the DOAC with the highest persistence. Dabigatran had the highest proportion of discontinuers and switchers at 12 months in most databases (EMA/2015/27/PH). | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject.en | Adherence | |
| dc.subject.en | Persistence | |
| dc.subject.en | Anticoagulants | |
| dc.subject.en | Non valvular atrial fibrillation | |
| dc.subject.en | Cardiovascular | |
| dc.subject.en | Drug utilization | |
| dc.subject.en | Pharmacoepidemiology | |
| dc.subject.en | Europe | |
| dc.title.en | Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008-2015) | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.3389/fphar.2021.682890 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 34803665 | en_US |
| bordeaux.journal | Frontiers in Pharmacology | en_US |
| bordeaux.page | 682890 | en_US |
| bordeaux.volume | 12 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | PharmacoEpi-Drugs | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.identifier.funderID | European Medicines Agency | en_US |
| hal.identifier | hal-03528331 | |
| hal.version | 1 | |
| hal.date.transferred | 2022-01-17T10:09:24Z | |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Frontiers%20in%20Pharmacology&rft.date=2021-11-03&rft.volume=12&rft.spage=682890&rft.epage=682890&rft.eissn=1663-9812%20(Print)%201663-9812%20(Linking)&rft.issn=1663-9812%20(Print)%201663-9812%20(Linking)&rft.au=SABATE,%20M.&VIDAL,%20X.&BALLARIN,%20E.&ROTTENKOLBER,%20M.&SCHMIEDL,%20S.&rft.genre=article |
